Vijayakumar A, Shaji S, Beena R, Sarada S, Rani TS, Stephen R, Manju RV, Viji MM
Miao M, Pan M, Chen X, Shen J, Zhang L, Feng X, Chen M, Cui G, Zong H, Zhang W, Chang S, Xu F, Wang Z, Li D, Liu W, Ding Z, Zhang S, Chen B, Zha X, Fan X (2024) IL-13 facilitates ferroptotic death in asthmatic epithelial cells via SOCS1-mediated ubiquitinated degradation of SLC7A11
GHK-Cu is the anti-aging anchor of the blend
For example, as some forms of Parkinsons disease are associated with mutations in lysosomal genes, PROTACs can be used to modulate -syn levels as demonstrated by Qu et al

Risk Factors for Adverse Reactions Some individuals may be at higher risk for side effects, and therefore, we recommend that you speak to a medical professional if you have any of the following: Pre-existing liver or kidney conditions Autoimmune disorders Hormone-sensitive conditions History of allergic reactions to peptides Long-Term Safety Considerations Its important to note several key facts about long-term safety: No human clinical trials have assessed long-term safety beyond several months Carcinogenicity (cancer-causing potential) has not been thoroughly studied The potential for developing antibodies against BPC 157 with prolonged use is unknown Possible tolerance development with continuous use has not been well-researched Long-term effects on hormone systems remain unclear Extent of Research on BPC 157 As it stands, BPC 157 still has some research gaps

Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: What can we learn from initial clinical trials